
https://www.science.org/content/blog-post/plants-cancer
# Article Title (Month Year)
Plants For Cancer?
January 2008

## 1. SUMMARY

The article critiques a New York Times piece profiling ethnobotanist Chris Kilham's plant-hunting activities in Peru. The original Times article presented Kilham's view that pharmaceutical companies underutilize medicinal plants and should embrace "pure plant medicine" used by indigenous peoples. Kilham argued Westerners are overmedicated with artificial compounds sold at huge markups, and that plant-derived medicines are safer alternatives that indigenous peoples have used successfully for thousands of years.

Key claims scrutinized include: a UN study stating 62% of FDA-approved cancer drugs derive from natural product discoveries; examples like ginseng, ginkgo biloba, and aloe vera generating billions in supplement sales; and the viability of "bioprospectors" making fortunes by discovering profitable plants.

The author challenges these assertions by dissecting what "natural" means (whole plants, extracts, or purified compounds), questioning whether plant medicines would avoid markups, noting that natural compounds show similar toxicity profiles to synthetic ones in genotoxicity studies, and examining the limited commercial success of natural product companies like Shaman Pharmaceuticals.

## 2. HISTORY

**Continued Decline of Direct Natural Products in Drug Discovery:** Following 2008, the trend away from direct natural product drug discovery accelerated. The biotech and pharmaceutical industries increasingly focused on synthetic compounds, biologics (especially monoclonal antibodies), and targeted therapies. Kinase inhibitors, immune checkpoint inhibitors, and CAR-T therapies dominated oncology innovation—nearly all fully synthetic or biological rather than natural product-derived.

**Clinical and Regulatory Outcomes:** The article's skepticism about natural products becoming major cancer therapies proved prescient. No major cancer drug emerged from traditional ethnobotanical prospecting in the subsequent years. Taxol (paclitaxel), mentioned in the original article, continued as an important chemotherapy agent, but its usage declined relative to newer targeted therapies. Semisynthetic derivatives like Taxotere maintained better market positions. However, the overall proportion of natural product-derived cancer drugs in the top-selling oncology medications continued to decrease.

**Supplement Industry Evolution:** The herbal supplement market grew substantially, reaching approximately $50+ billion globally by the 2020s, but this represented supplements rather than FDA-approved pharmaceuticals. Most products lacked rigorous clinical validation and operated in a regulatory gray area compared to approved drugs.

**Company Performance:** Companies focused on traditional ethnobotanical drug discovery continued to struggle. No significant pharmaceutical company achieved major commercial success through the bioprospecting model described in the article. Drug development costs remained high regardless of compound origin, and regulatory hurdles for plant-derived medicines proved equally challenging.

**Research Trends:** Academic natural product chemistry continued but with more sophisticated approaches including metagenomics, microbial fermentation, and engineered biosynthesis rather than traditional plant collection. The field moved toward understanding biosynthetic pathways and engineering production rather than direct plant extraction.

## 3. PREDICTIONS

• **Prediction (implied):** Natural product drug discovery would continue declining as kinase inhibitors and other synthetic compounds dominated oncology innovation.  
  **Outcome:** **Accurate.** The 2010s saw explosive growth in kinase inhibitors (more than 70 FDA-approved by the 2020s), immune checkpoint inhibitors, and CAR-T therapies—all synthetic or biological. Natural product-derived cancer drugs became a smaller fraction of new approvals and market share.

• **Prediction (implied):** The "pure plant medicine" movement advocated by Kilham would not become a major force in conventional cancer treatment.  
  **Outcome:** **Accurate.** Despite growth in supplement usage, conventional oncology continued to be dominated by synthetic pharmaceuticals and biologics. When cancer patients sought complementary approaches, they typically used these alongside conventional treatment rather than as replacements.

• **Prediction (explicit by Derek Lowe in article):** Natural products weren't dead but weren't an "untouched gold mine" either, and the 62% figure might represent a peak.  
  **Outcome:** **Accurate.** While natural products continued providing molecular scaffolds and inspiration (e.g., some COVID-19 antiviral candidates had natural product origins), they constituted a declining percentage of new molecular entities and blockbuster drugs after 2008.

• **Underlying concern:** The conflation of herbal supplements with pharmaceutical drug discovery would persist, maintaining separate markets with different regulatory standards and evidence requirements.  
  **Outcome:** **Accurate.** The supplement market thrived with lax regulation while pharmaceutical drug development became even more expensive and rigorous, with no convergence between these pathways.

## 4. INTEREST

Rating: **7/10**

This article remains highly relevant because it correctly identified the fundamental economics and scientific challenges that would limit natural product drug discovery, while the subsequent decade-plus validated these insights through actual industry outcomes. The piece demonstrates sophisticated understanding of drug development realities that contrast sharply with popular mythology about plant-based medicine.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20080104-plants-cancer.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_